Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
ACTIVE_NOT_RECRUITING
Status
Conditions
- Bladder Small Cell Neuroendocrine Carcinoma
- Bladder Squamous Cell Carcinoma
- Bladder Urothelial Carcinoma
- Clear Cell Renal Cell Carcinoma
- Invasive Bladder Plasmacytoid Urothelial Carcinoma
- Invasive Bladder Sarcomatoid Urothelial Carcinoma
- Invasive Sarcomatoid Urothelial Carcinoma
- Kidney Medullary Carcinoma
- Malignant Genitourinary System Neoplasm
- Malignant Solid Neoplasm
- Penile Carcinoma
- Penile Squamous Cell Carcinoma
- Renal Cell Carcinoma
- Renal Pelvis Urothelial Carcinoma
- Sarcomatoid Renal Cell Carcinoma
- Stage III Bladder Cancer AJCC v8
- Stage III Penile Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage III Renal Pelvis and Ureter Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Penile Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Stage IV Renal Pelvis and Ureter Cancer AJCC v8
- Stage IV Ureter Cancer AJCC v8
- Stage IV Urethral Cancer AJCC v8
- Ureter Urothelial Carcinoma
- Urethral Urothelial Carcinoma
Interventions
- PROCEDURE: Biopsy Procedure
- PROCEDURE: Biospecimen Collection
- DRUG: Cabozantinib S-malate
- PROCEDURE: Computed Tomography
- PROCEDURE: Echocardiography Test
- BIOLOGICAL: Ipilimumab
- PROCEDURE: Magnetic Resonance Imaging
- BIOLOGICAL: Nivolumab
Sponsor
National Cancer Institute (NCI)